Saturday, October 31, 2026

USD/CNH Is 1% Up In The Last 5 Sessions

USD/CNH Is 1% Up In The Last 5 Sessions

(VIANEWS) - USD/CNH (USDCNH) has been up by 1.52% for the last 5 sessions. At 19:06 EST on Wednesday, 27 March, USD/CNH (USDCNH) is $7.26.

USD/CNH's yearly highs and lows, it's 0.059% up from its 52-week low and 0.012% down from its 52-week high.

News about

  • According to FXStreet on Tuesday, 26 March, "The USD/JPY pair might then build on its well-established uptrend witnessed since January 2023. ", "This, in turn, should help limit any corrective decline for the USD/JPY pair ahead of the BoJ Core CPI later today and the US Personal Consumption Expenditures (PCE) Price Index data, scheduled for release on Friday."
  • Usd/jpy alternates gains with losses near 151.50. According to FXStreet on Monday, 25 March, "So far, USD/JPY is up 0.06% at 151.40 and faces the next resistance at the 2024 peak of 151.86 (March 22) ahead of the 2023 high of 151.90 (November 13) and the 2022 top of 151.94 (October 21. "
  • Usd/jpy: verbal intervention from Japanese officials to help dampen further upside in the near term – MUFG. According to FXStreet on Monday, 25 March, "However, we do expect verbal intervention from Japanese officials to help dampen further upside for USD/JPY in the near term. "
  • Usd/jpy stuck in a stalemate zone, fated to eventually fall. According to FXStreet on Tuesday, 26 March, "​​We still see scope for USD/JPY to drop to at least 140.00 by year-end with risks of a move to the mid-130.00's," adds MUFG.", "Institutional analysts are generally bearish about USD/JPY in the medium-to-long run. "

More news about USD/CNH (USDCNH).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com